Vedolizumab
- Generic Name
- Vedolizumab
- Brand Names
- Entyvio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943609-66-3
- Unique Ingredient Identifier
- 9RV78Q2002
- Background
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 intera...
- Indication
Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.
- Associated Conditions
- Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-04
- Target Recruit Count
- 45
- Registration Number
- NCT06066840
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT06045754
- Locations
- 🇺🇸
Gastroenterology Research of San Antonio, LLC, San Antonio, Texas, United States
🇺🇸Digestive Health Specialsits, Dothan, Alabama, United States
🇺🇸GI Alliance Sun City, Sun City, Arizona, United States
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 240
- Registration Number
- NCT05702879
- Locations
- 🇨🇭
University Hospital Bern Inselspital, Bern, Switzerland
Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2022-08-01
- Target Recruit Count
- 30
- Registration Number
- NCT05481619
- Locations
- 🇨🇳
Second Affiliated Hospital Zhejiang University School of Medicine, Zhengzhou, Hangzhou, China
A Multicentered Prospective Cohort Study of Chinese IBD Patients
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05386290
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05281614
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Benaroya Research Institute, Seattle, Washington, United States
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-12-05
- Target Recruit Count
- 438
- Registration Number
- NCT05205603
- Locations
- 🇨🇳
People's Hospital of Chongqing, Chongqing, Chongqing, China
🇨🇳Shunde Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 60
- Registration Number
- NCT04919252
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Vedolizumab for Immune Mediated Colitis
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 82
- Registration Number
- NCT04797325
- Locations
- 🇩🇰
Herlev University Hospital, Herlev, Denmark
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 120
- Registration Number
- NCT04779307
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Antwerpen, Belgium
🇧🇪Universitair Ziekenhuis Brussel - PIN, Jette, Brussels, Belgium
🇺🇸Phoenix Childrens Hospital -1919 E Thompson Rd, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.